Outcomes of children at 2 years after planned cesarean birth versus planned vaginal birth for breech presentation at term: The international randomized Term Breech Trial
Autor: | Amiram Gafni, Kofi Amankwah, Walter J. Hannah, Mary E. Hannah, Rose Kung, Hilary Whyte, Michael Helewa, Ellen Hodnett, Patricia Guselle, Eileen K. Hutton, Darren McKay, Sue Ross, Saroj Saigal, Sheila Hewson, Mary Cheng, Andrew R. Willan |
---|---|
Rok vydání: | 2004 |
Předmět: |
medicine.medical_specialty
Pediatrics Developmental Disabilities Gestational Age Nervous System law.invention Randomized controlled trial Pregnancy Risk Factors Breech presentation law Surveys and Questionnaires Infant Mortality medicine Humans Breech Presentation reproductive and urinary physiology Cesarean Section business.industry Obstetrics Infant Newborn Absolute risk reduction Obstetrics and Gynecology Gestational age Delivery Obstetric medicine.disease Infant mortality Clinical trial Treatment Outcome Child Preschool Relative risk Female business Follow-Up Studies |
Zdroj: | American Journal of Obstetrics and Gynecology. 191:864-871 |
ISSN: | 0002-9378 |
DOI: | 10.1016/j.ajog.2004.06.056 |
Popis: | Objective The purpose of this study was to determine whether planned cesarean delivery for the singleton fetus in breech presentation at term reduces the risk of death or neurodevelopmental delay at 2 years of age. Study design In selected centers in the Term Breech Trial, children were screened for abnormalities at ≥2 years of age with the Ages and Stages Questionnaire, followed by a neurodevelopmental assessment if the Ages and Stages Questionnaire score was abnormal. Results A total of 923 of 1159 children (79.6%) from 85 centers were followed to 2 years of age. The risk of death or neurodevelopmental delay was no different for the planned cesarean than for the planned vaginal birth groups (14 children [3.1%] vs 13 children [2.8%]; relative risk, 1.09; 95% CI, 0.52- 2.30; P =.85; risk difference, +0.3%; 95% CI, −1.9%, +2.4%). Conclusion Planned cesarean delivery is not associated with a reduction in risk of death or neurodevelopmental delay in children at 2 years of age. |
Databáze: | OpenAIRE |
Externí odkaz: |